Kornitzer Capital Management Inc. KS Decreases Position in Natera, Inc. (NASDAQ:NTRA)

Kornitzer Capital Management Inc. KS decreased its position in shares of Natera, Inc. (NASDAQ:NTRA) by 7.6% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 163,969 shares of the medical research company’s stock after selling 13,415 shares during the quarter. Kornitzer Capital Management Inc. KS owned 0.13% of Natera worth $20,816,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of NTRA. Itau Unibanco Holding S.A. purchased a new position in Natera in the 2nd quarter valued at about $28,000. Quarry LP raised its holdings in shares of Natera by 148.4% during the second quarter. Quarry LP now owns 318 shares of the medical research company’s stock valued at $34,000 after acquiring an additional 190 shares during the last quarter. GAMMA Investing LLC increased its position in shares of Natera by 50.0% during the second quarter. GAMMA Investing LLC now owns 324 shares of the medical research company’s stock worth $35,000 after purchasing an additional 108 shares in the last quarter. Tobam acquired a new stake in shares of Natera in the second quarter valued at about $74,000. Finally, Hanseatic Management Services Inc. boosted its position in Natera by 23.6% during the third quarter. Hanseatic Management Services Inc. now owns 891 shares of the medical research company’s stock worth $113,000 after acquiring an additional 170 shares during the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

Insider Buying and Selling

In other news, insider Jonathan Sheena sold 2,700 shares of the company’s stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $113.82, for a total transaction of $307,314.00. Following the completion of the transaction, the insider now owns 299,441 shares of the company’s stock, valued at $34,082,374.62. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In related news, insider Jonathan Sheena sold 2,700 shares of Natera stock in a transaction on Monday, August 12th. The shares were sold at an average price of $113.82, for a total transaction of $307,314.00. Following the transaction, the insider now owns 299,441 shares in the company, valued at approximately $34,082,374.62. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Michael Burkes Brophy sold 1,866 shares of the business’s stock in a transaction dated Thursday, October 31st. The stock was sold at an average price of $126.45, for a total value of $235,955.70. Following the transaction, the chief financial officer now owns 68,851 shares in the company, valued at approximately $8,706,208.95. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 50,164 shares of company stock worth $6,157,291. 7.60% of the stock is owned by insiders.

Natera Stock Performance

Natera stock traded up $2.32 during mid-day trading on Thursday, reaching $129.29. 61,604 shares of the company were exchanged, compared to its average volume of 1,302,589. Natera, Inc. has a twelve month low of $40.61 and a twelve month high of $133.54. The firm has a market cap of $15.99 billion, a PE ratio of -51.82 and a beta of 1.53. The company has a debt-to-equity ratio of 0.34, a quick ratio of 4.01 and a current ratio of 4.14. The firm’s 50-day simple moving average is $123.75 and its two-hundred day simple moving average is $113.16.

Natera (NASDAQ:NTRA) last released its quarterly earnings data on Thursday, August 8th. The medical research company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.69) by $0.39. The firm had revenue of $413.35 million during the quarter, compared to the consensus estimate of $343.00 million. Natera had a negative return on equity of 36.74% and a negative net margin of 21.47%. Natera’s quarterly revenue was up 58.1% on a year-over-year basis. During the same period last year, the business posted ($0.97) EPS. Equities analysts predict that Natera, Inc. will post -1.96 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the stock. Morgan Stanley raised their price objective on shares of Natera from $125.00 to $132.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 13th. Leerink Partners raised their price target on shares of Natera from $140.00 to $150.00 and gave the stock an “outperform” rating in a report on Thursday, October 17th. Sanford C. Bernstein upped their price objective on Natera from $125.00 to $135.00 and gave the company an “outperform” rating in a report on Wednesday, October 30th. Piper Sandler reissued an “overweight” rating and set a $150.00 target price on shares of Natera in a research note on Friday, September 13th. Finally, The Goldman Sachs Group upped their price target on Natera from $125.00 to $140.00 and gave the company a “buy” rating in a research note on Wednesday, October 16th. One analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $125.69.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.